Bristol melanoma drug combo marks new advance in immunotherapy
By Julie Steenhuysen CHICAGO (Reuters) - Melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for treatments that harness the body's immune system to fight cancer. Bristol released preliminary data from the early-stage trial on Wednesday, with more detailed results expected to highlight the American Society ...
Tags:
Bristol melanoma drug combo marks new advance in immunotherapy,
Melanoma Latest News